In the latest trading session, Eli Lilly (LLY) closed at $804.99, marking a -0.39% move from the previous day.

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new ...

Bloomfield Hills internal medicine physician Amjad Rass was excited to reunite with family in Syria last month for the first ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday ...

Orlando Health Orlando Regional Medical Center has debuted its redesigned emergency room downtown. The nonprofit health ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...